Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition
- PMID: 11705631
- DOI: 10.1016/s0197-4580(01)00245-7
Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition
Abstract
Vaccinations with Abeta1-42 have been shown to reduce amyloid burden in transgenic models of Alzheimer's disease (AD). We have further tested the efficacy of Abeta1-42 immunization in the Tg2576 mouse model of AD by immunizing one group of mice with minimal Abeta deposition, one group of mice with modest Abeta deposition, and one group with significant Abeta deposition. The effects of immunization on Abeta deposition were examined using biochemical and immunohistochemical methods. In Tg2576 mice immunized prior to significant amyloid deposition, Abeta1-42 immunization was highly effective. Biochemically extracted Abeta40 and Abeta42 levels were significantly reduced and immunohistochemical plaque load was also reduced. Immunization of mice with modest amounts of pre-existing Abeta deposits selectively reduced Abeta42 without altering Abeta40, although plaque load was reduced. In contrast, in Tg2576 mice with significant pre-existing Abeta loads, Abeta1-42 immunization only minimally decreased Abeta42 levels, whereas no alteration in Abeta40 levels or in plaque load was observed. These results indicate that in Tg2576 mice, Abeta1-42 immunization is more effective at preventing additional Abeta accumulation and does not result in significant clearance of pre-existing Abeta deposits.
Similar articles
-
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.J Neurosci. 2003 Sep 17;23(24):8532-8. doi: 10.1523/JNEUROSCI.23-24-08532.2003. J Neurosci. 2003. PMID: 13679422 Free PMC article.
-
Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.Curr Alzheimer Res. 2017;14(6):656-667. doi: 10.2174/1567205013666161201201227. Curr Alzheimer Res. 2017. PMID: 27915995
-
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.J Clin Invest. 2006 Jan;116(1):193-201. doi: 10.1172/JCI25410. Epub 2005 Dec 8. J Clin Invest. 2006. PMID: 16341263 Free PMC article.
-
Novel Abeta immunogens: is shorter better?Curr Alzheimer Res. 2007 Sep;4(4):427-36. doi: 10.2174/156720507781788800. Curr Alzheimer Res. 2007. PMID: 17908047 Review.
-
A safer vaccine for Alzheimer's disease?Neurobiol Aging. 2002 Nov-Dec;23(6):1001-8. doi: 10.1016/s0197-4580(02)00124-0. Neurobiol Aging. 2002. PMID: 12470795 Review.
Cited by
-
The roles of neutral sphingomyelinases in neurological pathologies.Neurochem Res. 2012 Jun;37(6):1137-49. doi: 10.1007/s11064-011-0692-y. Epub 2012 Jan 12. Neurochem Res. 2012. PMID: 22237969 Review.
-
Neuroprotective effects of curcumin.Adv Exp Med Biol. 2007;595:197-212. doi: 10.1007/978-0-387-46401-5_8. Adv Exp Med Biol. 2007. PMID: 17569212 Free PMC article. Review.
-
IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.J Neurosci. 2005 Dec 14;25(50):11495-503. doi: 10.1523/JNEUROSCI.3697-05.2005. J Neurosci. 2005. PMID: 16354907 Free PMC article.
-
Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.CNS Neurol Disord Drug Targets. 2009 Apr;8(2):88-97. doi: 10.2174/187152709787847315. CNS Neurol Disord Drug Targets. 2009. PMID: 19355930 Free PMC article. Review.
-
Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice.J Neurosci. 2009 Apr 15;29(15):4964-71. doi: 10.1523/JNEUROSCI.4560-08.2009. J Neurosci. 2009. PMID: 19369565 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical